Abstract | BACKGROUND/AIM: PATIENTS AND METHODS: In this retrospective study we examined patients with nmCRPC that received vintage hormone therapy as AADT between 1999 and 2018. RESULTS: Of 53 patients with nmCRPC, 25 patients (47.2%) had stage 1 nodal disease (N1) at diagnosis of nmCRPC. Prostate specific antigen (PSA) reduction rate≥30% was observed in 32 patients (72.7%). The median PSA nadir was 0.7, and the duration of the response was 14.3 months. The median metastasis-free survival (MFS) for the entire patient population was 62.2 months, and the median overall survival (OS) was not reached. In the multivariate analysis, the duration of response in AADT>18 months was a predictor of prolonged OS. CONCLUSION: There is a certain number of nmCRPC patients who respond well to vintage hormone therapy as AADT. Further studies are expected to differentiate such cases.
|
Authors | Hiroaki Iwamoto, Hiroshi Kano, Takafumi Shimada, Renato Naito, Tomoyuki Makino, Suguru Kadamoto, Hiroshi Yaegashi, Kazuyoshi Shigehara, Kouji Izumi, Yoshifumi Kadonoa, Atsushi Mizokami |
Journal | In vivo (Athens, Greece)
(In Vivo)
2021 Mar-Apr
Vol. 35
Issue 2
Pg. 1247-1252
ISSN: 1791-7549 [Electronic] Greece |
PMID | 33622927
(Publication Type: Journal Article)
|
Copyright | Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. |
Chemical References |
- Androgen Antagonists
- Androgens
|
Topics |
- Androgen Antagonists
(therapeutic use)
- Androgens
- Humans
- Japan
- Male
- Prostatic Neoplasms, Castration-Resistant
(drug therapy)
- Retrospective Studies
|